Basmisanil

Basmisanil
Clinical data
Other names	RG-1662; RO5186582
ATC code	None;
Identifiers
	IUPAC name (1,1-Dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone;
CAS Number	1159600-41-5;
PubChem CID	57336276;
ChemSpider	34500832;
UNII	788PET5SUA;
KEGG	D10863 ;
CompTox Dashboard (EPA)	DTXSID201032402 ;
Chemical and physical data
Formula	C21H20FN3O5S
Molar mass	445.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4;
	InChI InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3; Key:VCGRFBXVSFAGGA-UHFFFAOYSA-N;

Basmisanil (INNTooltip International Nonproprietary Name; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α₅ subunit-containing GABA_A receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.^[1]^[2]^[3] As of June 2016, it is no longer studied for this purpose.^[4] It underwent a clinical trial for cognitive impairment in patients with schizophrenia.^[5]

References

^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". Journal of Alzheimer's Disease. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
^ Hurley D (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
^ Jensen HS, Nichol K, Lee D, Ebert B (2014). "Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes". PLOS ONE. 9 (2): e88456. Bibcode:2014PLoSO...988456J. doi:10.1371/journal.pone.0088456. PMC 3922815. PMID 24533090.
^ Chevrette M. "Response to the Roche Clinical Trial for CLEMATIS". Archived from the original on 2017-12-22. Retrieved 2016-06-28.
^ Clinical trial number NCT02953639 for "A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics" at ClinicalTrials.gov